CD19 and neoplasm: Correspondingly, the concurrent administration of ibrutinib and CD19-specific CAR-T cells could improve CAR-T-cell engraftment, resulting in enhanced tumor clearance and survival in murine models of resistant ALL and chronic lymphocytic leukemia (CLL) [39].